General
Preferred name
ENOXIMONE
Synonyms
Enoximonum ()
MDL-17043 ()
Perfan ()
MDL 17,043 ()
P&D ID
PD002748
CAS
77671-31-9
Tags
natural product
drug
available
First approval
1988
Drug Status
investigational
approved
Drug indication
Congestive heart failure
Cardiotonic
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Enoximone is a selective phosphodiesterase inhibitor, targeting PDE3 subtypes . It is a cardiotonic agent .
(GtoPdb)
DESCRIPTION
Selective phosphodiesterase III (PDE III) inhibitor
(LOPAC library)
DESCRIPTION
PDE inhibitor (non-selective)
(Tocris Bioactive Compound Library)
DESCRIPTION
Enoximone is a selective phosphodiesterase III (PDE3) inhibitor. It can be used for the treatment of heart failure.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
3
Compound Sets
20
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
31
Molecular Weight
248.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
1.96
TPSA
65.72
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
PDE III
Pathway
Metabolism
Metabolic Enzyme/Protease
Target
PDE3
PDE3A
Phosphodiesterase (PDE)
Primary Target
Phosphodiesterases
MOA
Inhibitor
phosphodiesterase inhibitor
Indication
congestive heart failure
Therapeutic Class
Cardiotonic Agents
Solubility
DMSO: soluble28 mg/mL
Source data
